Technical Analysis for ZLAB - Zai Lab Limited
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical ZLAB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 15 | Above Upper BB | Strength | 2.82% |
| Jan 15 | Overbought Stochastic | Strength | 2.82% |
| Jan 15 | Upper Bollinger Band Touch | Strength | 2.82% |
| Jan 14 | Slingshot Bullish | Bullish Swing Setup | 10.28% |
| Jan 14 | Overbought Stochastic | Strength | 10.28% |
| Jan 14 | Upper Bollinger Band Touch | Strength | 10.28% |
| Jan 11 | Pocket Pivot | Bullish Swing Setup | 7.54% |
| Jan 11 | Doji - Bearish? | Reversal | 7.54% |
| Jan 11 | Overbought Stochastic | Strength | 7.54% |
| Jan 11 | Up 3 Days in a Row | Strength | 7.54% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ZLAB news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 27.34 |
| 52 Week Low | 14.29 |
| Average Volume | 145,825 |
| 200-Day Moving Average | 20.7421 |
| 50-Day Moving Average | 20.27 |
| 20-Day Moving Average | 22.772 |
| 10-Day Moving Average | 23.317 |
| Average True Range | 1.3395 |
| ADX | 38.47 |
| +DI | 36.3744 |
| -DI | 12.8243 |
| Chandelier Exit (Long, 3 ATRs ) | 21.9115 |
| Chandelier Exit (Short, 3 ATRs ) | 24.2385 |
| Upper Bollinger Band | 25.1842 |
| Lower Bollinger Band | 20.3598 |
| Percent B (%b) | 1.11 |
| BandWidth | 21.185667 |
| MACD Line | 1.1546 |
| MACD Signal Line | 1.0022 |
| MACD Histogram | 0.1524 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.26 Billion |
| Num Shares | 49.1 Million |
| EPS | -4.94 |
| Price-to-Earnings (P/E) Ratio | -5.21 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 28.81 | ||||
| Resistance 3 (R3) | 28.53 | 27.23 | 28.29 | ||
| Resistance 2 (R2) | 27.23 | 26.45 | 27.37 | 28.12 | |
| Resistance 1 (R1) | 26.48 | 25.96 | 26.86 | 26.76 | 27.95 |
| Pivot Point | 25.18 | 25.18 | 25.37 | 25.32 | 25.18 |
| Support 1 (S1) | 24.43 | 24.40 | 24.81 | 24.71 | 23.51 |
| Support 2 (S2) | 23.13 | 23.91 | 23.27 | 23.34 | |
| Support 3 (S3) | 22.38 | 23.13 | 23.17 | ||
| Support 4 (S4) | 22.66 |
